Brain Tumors

Supratentorial Craniotomy

Supratentorial Craniotomy: Inpatient Mortality

ᵃ3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality. solutions.3m.com/wps/portal/3M/en_US/Health-Information-Systems/HIS/Products-and-Services/Products-List-A-Z/APR-DRG-Software.

Inpatient mortality remained lower than expected, continuing the trend over the past 5 years. N = number of supratentorial craniotomies performed for brain tumor per year.

Supratentorial Craniotomy: Length of Stay

LOS = length of stay

ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality. solutions.3m.com/wps/portal/3M/en_US/Health-Information-Systems/HIS/Products-and-Services/Products-List-A-Z/APR-DRG-Software.

Mean length of stay (LOS) remained below expected, continuing the trend over the past 5 years.

Supratentorial Craniotomy: Karnofsky Performance Scale (N = 139)

2017

Functional status is measured by the Karnofsky Performance Scale (KPS), a widely used 11-point scale correlating to percentage values from 100% (no evidence of disease, no symptoms) to 0% (death). Performance status was stable or improved in approximately 89% of patients immediately after supratentorial craniotomy. Change in KPS status was defined as a change of ≥ 20 points.

Supratentorial Craniotomy: Survival by Tumor Type – Glioma

The 30- and 180-day survival rates for supratentorial craniotomy for glioma were 100% and 98%, respectively (for the first 6 months of 2017).

Supratentorial Craniotomy: Survival by Tumor Type – Meningioma

Both 30- and 180-day survival rates for supratentorial craniotomy for meningioma were 96.8% (for the first 6 months of 2017).

Supratentorial Craniotomy: Survival by Tumor Type – Metastasis

The 30- and 180-day survival rates for supratentorial craniotomy for metastases were 96.2% and 92.3%, respectively (for the first 6 months of 2017).